Q-Line Biotec has launched its initial public offering today, marking the company's entry into the public markets. According to reports from Upstox Securities, the IPO is exclusively structured as a fresh issuance of 62.53 lakh shares, with no offer for sale (OFS) component included in the offering. The IPO is scheduled to open on Thursday, May 21, 2026, and will close on Monday, May 25, 2026, with anchor bidding taking place on Wednesday, May 20, 2026. Bidding is open from 10:00 AM to 5:00 PM on public issue days, with the issue valued at ₹214.48 crore. The company has announced a price band of ₹326-₹343 per share with a minimum application of 800 shares and multiples thereof.
The IPO has received strong investor response with ₹178.12 crore subscribed on the first day, as per latest reports from BSE and NSE. The issue offers 62.53 lakh equity shares with specific allocation across categories: ₹178.12 crore from QIBs (47.48%), ₹61.10 crore from anchor investors (28.48%), ₹30.58 crore from NIIs (14.26%), and ₹71.32 crore from retail investors (33.25%). The company has allocated 3.13 lakh shares to market makers representing 5.01% of the total issue size. The final basis of allotment is expected on Tuesday, May 26, 2026, with shares credited to demat accounts on the same day. The IPO constitutes 26.81% of the post-IPO paid-up capital of the company.
The IPO is being managed by HEM Securities Limited & Share India Capital Services Private Limited as the Book Running Lead Managers, and Purva Sharegistry (India) Private Limited as the Registrar. According to the regulatory filings, the issue size comprises 62,53,200 equity shares with specific allocation for Qualified Institutional Buyers (QIB), Non-Institutional Investors, and Individual Investors. The company's shares will be listed on the NSE SME Emerge platform with listing scheduled for Friday, May 29, 2026. From the net proceeds of the IPO, the company will utilize ₹93.50 crore for working capital, ₹90.00 crore for repayment/prepayment of certain borrowings, and the remainder for general corporate purposes. The company raised ₹27.44 crore in a pre-IPO placement of 800,000 shares in May 2026, at ₹343 per share.
Q-Line Biotec Limited is an Indian in-vitro diagnostics (IVD) and healthcare solutions company incorporated in November 2010, engaged in manufacturing and supplying diagnostic reagents, rapid test kits, molecular diagnostics, pathology equipment, and related consumables used by hospitals, laboratories, and healthcare institutions across India. The company's operations span clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and other POC devices, with indigenous manufacturing capabilities for reagents and in-vitro diagnostics. During the Covid-19 pandemic, the company diversified its focus and developed a range of RT-PCR Kits, RNA Extraction Kits, and VTM Kits through technical collaboration with third-party institutes and its own R&D team. The company currently operates on a B2B model supplying products to distributors, diagnostic service providers, and hospitals, with revenue distribution of 56% from reagents, 37% from instruments, and 4.5% from consumables/spares in FY25.
The company has demonstrated strong financial growth with total income of ₹184.81 crore and net profit of ₹32.10 crore in FY23, growing to ₹322.58 crore revenue and ₹28.13 crore net profit in FY25. For the 9M-FY26 period ended December 31, 2025, the company earned net profit of ₹38.69 crore on total income of ₹236.50 crore. The company has reported an average EPS of ₹25.00 and average RoNW of 23.17% for the last two fiscals. However, the issue appears fully priced based on its bumper earnings for 9M-FY26, which may not be sustainable. The company's P/E ratio stands at 15.51 based on FY26 super earnings and P/BV ratio of 2.44 based on NAV of ₹140.81 per share as of December 31, 2025. The company has 362 employees on payroll and 223 contract employees as of March 31, 2026, with 19 personnel at R&D laboratories constituting 5.25% of total employee strength.
